Phase 3 ORIENT-3 study results for sintilimab injection (TYVYT) as a second-line treatment for squamous non-small cell lung cancer shows benefit

Study (n=290) found statistically significant improvement in overall survival (OS) for sintilimab, an anti-PD-1 inhibitor vs docetaxel, meeting the primary endpoint. Median OS was 11.79 vs 8.25 months, respectively (HR=0.74 95% CI 0.56-0.96 P=0.02489).

Biospace Inc.